162 related articles for article (PubMed ID: 32484618)
1. Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Leisenring NH; Rogers JL; Telloni S; Mansoori P; Al-Rohil RN; Marano AL
J Drugs Dermatol; 2020 May; 19(5):544-546. PubMed ID: 32484618
[TBL] [Abstract][Full Text] [Related]
2. Two cases of lupus arteritis: a rare type of cutaneous lupus vasculitis.
Kato Y; Ohashi T; Yamamoto T
Int J Dermatol; 2019 Apr; 58(4):E85-E87. PubMed ID: 30548253
[No Abstract] [Full Text] [Related]
3. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
Lancet Haematol; 2016 Feb; 3(2):e72-9. PubMed ID: 26853646
[TBL] [Abstract][Full Text] [Related]
4. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
[TBL] [Abstract][Full Text] [Related]
5. A case of livedoid vasculopathy associated with factor V Leiden mutation: successful treatment with oral warfarin.
Kavala M; Kocaturk E; Zindanci I; Turkoglu Z; Altintas S
J Dermatolog Treat; 2008; 19(2):121-3. PubMed ID: 18484430
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of refractory cutaneous lupus vasculitis with i.v. immunoglobulin.
Takamuki R; Okiyama N; Inoue S; Endo R; Kondo Y; Chino Y; Sumida T; Fujimoto M
J Dermatol; 2019 Jul; 46(7):e253-e255. PubMed ID: 30714643
[No Abstract] [Full Text] [Related]
7. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
[TBL] [Abstract][Full Text] [Related]
8. [Recurrent leg ulcers due to livedoid vasculopathy: successful treatment with low-molecular-weight heparin].
Becker A; Stoffels-Weindorf M; Schimming T; Dissemond J
Dtsch Med Wochenschr; 2013 Jul; 138(28-29):1458-62. PubMed ID: 23821447
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations.
Micheletti RG
Clin Dermatol; 2018; 36(4):561-566. PubMed ID: 30047438
[TBL] [Abstract][Full Text] [Related]
10. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia.
Browning CE; Callen JP
Arch Dermatol; 2006 Jan; 142(1):75-8. PubMed ID: 16415390
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
[No Abstract] [Full Text] [Related]
12. [Liveoid vasculopathy with combined thrombophilia: efficacy of iloprost].
Magy N; Algros MP; Racadot E; Gil H; Kantelip B; Dupond JL
Rev Med Interne; 2002 Jun; 23(6):554-7. PubMed ID: 12108180
[TBL] [Abstract][Full Text] [Related]
13. [A case of cutaneous vasculitis in a patient with systemic lupus erythematosus].
Mastej K; Knapik-Kordecka M; Adamiec R
Pol Arch Med Wewn; 2005 Jan; 113(1):63-7. PubMed ID: 16130603
[TBL] [Abstract][Full Text] [Related]
14. Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban.
Lee JM; Kim IH
Clin Exp Dermatol; 2016 Jul; 41(5):559-61. PubMed ID: 26993107
[No Abstract] [Full Text] [Related]
15. Lupus-anticoagulant testing at NOAC trough levels.
Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic algorithm for Raynaud's phenomenon and vascular skin lesions in systemic lupus erythematosus.
Richter JG; Sander O; Schneider M; Klein-Weigel P
Lupus; 2010 Aug; 19(9):1087-95. PubMed ID: 20693202
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
[TBL] [Abstract][Full Text] [Related]
18. Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome?
Sopeña B; Pérez-Rodríguez MT; Rivera A; Ortiz-Rey JA; Lamas J; Freire-Dapena MC
Lupus; 2010 Oct; 19(11):1340-3. PubMed ID: 20659971
[TBL] [Abstract][Full Text] [Related]
19. Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban.
Miguel D; Elsner P; Goetze S
Clin Exp Dermatol; 2020 Jan; 45(1):120-122. PubMed ID: 30767258
[No Abstract] [Full Text] [Related]
20. [Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies].
Grasland A; Crickx B; Blanc M; Pouchot J; Vinceneux P
Ann Med Interne (Paris); 2000 Sep; 151(5):408-10. PubMed ID: 11033476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
